Comprehensive HHT Outcomes Registry of the United States (CHORUS)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States
Overview
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: * Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. * Be asked study-related questions by phone or at a clinic visit. * Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT.
Detailed description
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is a research initiative led by the HHT Foundation International, Inc. ("Cure HHT"). The study focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder characterized by the development of abnormal blood vessels in various organs of the body, including the brain, spine, lungs, liver, GI tract, skin, nasal mucosa, and oral cavity. The prevalence of HHT is estimated to be 1 in 5000, affecting children and adults. These abnormal blood vessels can lead to acute and chronic bleeding, stroke, heart failure, and death. Treatments are currently predominately limited to managing complications, while approximately 90% of adults have ongoing symptoms, despite the best surgical and medical therapies. With recent drug developments related to angiogenesis, there is hope for effective novel therapies.
A natural history registry for HHT has significant implications for improving the understanding and management of this rare genetic disorder. The purpose of this study is to better understand HHT, the symptoms and complications it causes ("outcomes"), and to understand how the disease impacts people's lives. The investigators hypothesize that a natural history registry for HHT will improve our understanding of the disease, lead to better management of patients, and ultimately, contribute to developing novel therapies to treat this disease.
The investigators will collaborate with multiple HHT Centers of Excellence across the U.S. to establish a comprehensive registry of HHT patients. The study aims to enroll approximately 10,000 HHT patients over a 10-year period. Longitudinal data will be collected both retrospectively and prospectively, with a focus on increasing the understanding of this rare disease, accelerating the development of new diagnostic and treatment options, and working collaboratively with clinicians who care for individuals with HHT to identify and address gaps in the system of care, especially those from underserved populations.
The study aims to serve as a centralized resource for future clinical trials and research in HHT. Data security and confidentiality are prioritized, and participants have the option to withdraw from the study at any time. The study is funded by the U.S. Department of Health Resources and Service Administration (HRSA) through a grant awarded to Cure HHT.
Primary outcome measures
- Comprehensive Baseline Data Collection using HHT Baseline Assessment Scale [Time frame: 10 years]
- Prospective Longitudinal Clinical Outcomes Assessment using HHT Clinical Outcomes Scale [Time frame: 10 years]
Secondary outcome measures (4)
- Identify severe morbidity and mortality outcomes related to HHT using HHT Clinical Outcomes Scale [Time frame: 10 years]
- Epistaxis Characterization with Epistaxis Severity Scale [Time frame: 10 years]
- Organ Vascular Malformation (VM) Development and Growth Assessment using Organ VMs Assessment Tool [Time frame: 10 years]
- Treatment Outcomes Assessment with HHT Treatment Outcomes Scale [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.
- Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.
Exclusion criteria
- Unable to provide informed consent or informed consent via a parent or legally authorized representative.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 16 centers
- University of Alabama at Birmingham — Birmingham
- University of California, Los Angeles — Los Angeles
- University of California, San Francisco — San Francisco
- University of Colorado, Denver — Aurora
- Yale University — New Haven
- Augusta University — Augusta
- Massachusetts General Hospital — Boston
- Mayo Clinic — Rochester
- … and 8 more centers
Publications
- Al-Samkari H, Friday C, Kasthuri RS, Gossage JR, Murphy CG, Hountras P, Smith KL, Kirkland K, Iyer V, Prasad V, Ahluwalia V, Rodriguez-Lopez J, Witkin AS, Conrad M, Hetts S, Ohliger M, Chakinala M, Sisk BA, Beasley MA, Kirkpatrick P, Lindquist J, Battaile JT, Lu A, Parambil J, McCrae K, Sheynzon V, Whitehead K, Sion C, McWilliams J, Cusumano LR, Trerotola SO, Drivas TG, Chesnutt M, Kaufman C, Dick PMID 41843464
Identifiers
NCT: NCT06259292 · HHT001